Alcohol Pharmacotherapy for HIV+ Prisoners

Diseases and Conditions Researched

AIDS; Alcohol Dependence; Hazardous Drinking; Human Immunodeficiency Virus; Problem Drinking

What is the purpose of this trial?

This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of reincarceration.

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsors: National Institute on Alcohol Abuse and Alcoholism (NIAAA); Yale University
Dates: February 19, 2010
Last Updated: July 8, 2014
Study HIC#: 0908005572 ID: NCT01077310